Jagsonpal Pharmaceuticals (JAGSNPHARM) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 revenue reached INR 74.7 crores (₹747 million), up 29.2% YoY, driven by core business growth and Yash Pharma integration.

• Net profit for Q2 FY25 rose 53% YoY to INR 11.4 crores (₹114 million), with a net margin of 15.3%.

• Operating EBITDA for Q2 FY25 increased 46.6% YoY to INR 18.4 crores (₹184 million), with margins expanding to 24.6%.

• H1 FY25 revenue was INR 136.1 crores (₹1,361 million), up 15.3% YoY, with net profit up 12% to INR 16.8 crores (₹168 million).

• Board approved a stock split (face value from INR 5 to INR 2), pending shareholder approval, to enhance liquidity.

Financial highlights

• Q2 FY25 revenue: INR 74.7 crores (₹747 million, +29.2% YoY); H1 FY25: INR 136.1 crores (₹1,361 million, +15.3% YoY).

• Q2 FY25 operating EBITDA: INR 18.4 crores (₹184 million, +46.6% YoY); H1 FY25: INR 31.1 crores (₹311 million, +22.4% YoY).

• Q2 FY25 net profit: INR 11.4 crores (₹114 million, +53% YoY); H1 FY25 net profit: INR 16.8 crores (₹168 million, +12% YoY).

• Q2 FY25 operating margin (pre-ESOP): 24.6% (+290 bps YoY); H1 FY25: 22.8% (+130 bps YoY).

• Cash and equivalents as of September 30, 2024: INR 93.4 crores (₹934 million), up INR 15.8 crores (₹158 million) in H1.

Outlook and guidance

• FY25 revenue growth expected at 30%+ with operating margins (pre-ESOP) around 22%.

• Organic revenue growth guidance of 12–14% annually, with margin expansion of 100–150 bps targeted for the next 3–4 years.

• Long-term margin target is to approach 30% EBITDA as scale improves.

• Cash to be deployed for strategic inorganic initiatives.

• Stock split expected to complete within three months of shareholder approval.